Eli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetes
In a recently completed phase III study, Jardiance demonstrated statistically significant improvement in blood sugar levels of children with type 2 diabetes.
by christian bundgaard, translated by catherine brett
Eli Lilly and Boehringer Ingelheim’s type 2 diabetes drug Jardiance is one step closer to a label expansion, after the drug performed well in a pediatric study.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Novo Nordisk shot helps teens lose weight, new study finds
For subscribers
